The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.
 
Ronald De Wit
Honoraria - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Daniel E. Castellano
No Relationships to Disclose
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Aristotelis Bamias
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Aude Flechon
Honoraria - Astellas Medivation; AstraZeneca; BMS Brazil; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; BMS Brazil; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ferring; Janssen; Lilly; MSD; Novartis
 
Alexandra Drakaki
Consulting or Advisory Role - Bristol-Myers Squibb
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Genentech/Roche; Incyte; Janssen; Lilly; Merck
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)
 
Oday Hamid
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Annamaria Zimmermann
Employment - Lilly
 
Ling Gao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Amanda Long
Employment - Lilly
 
Richard A. Walgren
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent applicant/holder, without royalties, for therapeutic applications related to ramucirumab and merestinib. (Inst)
 
Katherine M. Bell-McGuinn
Employment - Lilly
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi